Imports of blood drug approvedChina approves imports of recombinant factor VIII.
What an interesting little article!
We can complain, whether on the left, right or center, about U.S. government bureaucracy, the FDA, etc. But how about this gem,
“The authorities imposed the ban in 1986, in response to a case of HIV infection caused by imported factor VIII that was detected around 1983.”
So the Chinese communists banned foreign-made factor for 20 years although there hasn’t been a case of viral transmission from a factor product since 1990-1991 (reference needed). Interesting.
And how about this:
“Larry Zhang, regional head for Asia Pacific of Bayer Healthcare, said the treatment would be made available at a lower price in China than in other countries because of the financial difficulties that many patients here face and the lack of a comprehensive health insurance scheme.”
“…lack of a comprehensive health insurance scheme.” In other words the deep pockets of a third party payer.
“Recombinant-clotting factor will cost no more than 5 yuan (65 cents) in China, Zhang said. The average international price is 30 yuan.”
I’m no math whiz but if 5 yuan is $.65 then the average international price of 30 yuan is $3.90. That seems to be about 2-3 times the U.S. price (or at least a reasonable U.S. price).
Doc's a role model in triathlonHemophilia doc runs marathons and triathlons. Calling Dr. Hoots to the starting line.
Is Flamel Catching On?From the Motley fool:
Flamel Technologies has signed a deal to develop an improved formulation of an unnamed Wyeth drug.
"BeneFIX and ReFacto both fit the criteria for compounds that could benefit from Flamel's Medusa platform. They are proteins for which a new long-lasting formulation would definitely increase patient convenience and compliance, especially since they are administered intravenously or via an injection. Equally as important is that the drugs lose patent protection in 2011 and 2010, respectively."Competition for longer lasting factor products is always welcome. Choice and competition can only benefit the consumer.